Researchers at the US Army Institute of Surgical Research (USAISR) tested SBS-1000, Sparian’s first-in-class arylepoxamide receptor (AEAr) agonist, in an animal study of post-traumatic pain. In a well-established model of extremity trauma (ET), rats underwent a soft-tissue injury and fibula fracture. On day 3 post-ET, animals received a single dose of SBS-1000 (1 mg/kg SC) or vehicle (n = 16 per group) and were tested for mechanical allodynia and thermal hyperalgesia for up to 6 hours post-dose. Brains were then dissected and analyzed for expression of inflammatory mediators.
Key takeaways for SBS-1000:
- Reduces post-trauma pain: a single dose decreased injury-related allodynia and hyperalgesia by 50–75% versus vehicle for up to 6 hours (P < .05 to P < .001).
- No sedation: no effect on motor coordination or alertness.
- Lowers cytokine markers of inflammation: IL-2, TNF-α, IL-13, and IL-18 were reduced by 30–50% in the prefrontal cortex and thalamus (P < .05).
The results support SBS-1000 as a potential non-opioid option for treating pain on the battlefield and beyond. The work, conducted in collaboration with Sparian Biosciences, was funded by the Combat Casualty Care Research Program.
Sparian Biosciences is a clinical-stage CNS-focused biopharmaceutical company committed to developing transformational therapies to address significant medical needs specifically pain and substance use disorders. The company was co-founded by Jeffrey B. Reich MD, and Gavril Pasternak MD/PhD, and was spun out of Memorial Sloan Kettering Cancer Center (MSK). Sparian has five programs that address acute and chronic pain, opioid use disorder, opioid withdrawal syndrome, acute opioid overdose, and stimulant use disorder. Sparian is the recipient of five NIH/NIDA grants worth nearly $75 million. For more information, visit www.sparianbiosciences.com.
MSK has financial interests in Sparian.
Annie Pasternak
Chief Operating Officer
annie@sparianbiosciences.com
Brian Korb
astr partners
brian.korb@astrpartners.com
